| 1 | Non-Motor Fluctuations in Parkinson’s Disease: Underdiagnosed Yet Important | 1.6 | 22 | Citations (PDF) |
| 2 | Prodromal Parkinson’s Disease | 2.6 | 6 | Citations (PDF) |
| 3 | Conversion between <scp>NMSS</scp> and <scp>MDS</scp>‐<scp>NMS</scp> in Parkinson's Disease | 4.6 | 1 | Citations (PDF) |
| 4 | Early thinking palliative care for people with Parkinson's disease: A thematic synthesis based on a systematic mixed-methods review | 3.3 | 11 | Citations (PDF) |
| 5 | Glucagon-like peptide-1 receptor agonists in neurodegenerative diseases: Promises and challenges | 9.1 | 19 | Citations (PDF) |
| 6 | Evaluation of the effect of bilateral subthalamic nucleus deep brain stimulation on fatigue in Parkinson’s Disease as measured by the non-motor symptoms scale | 1.6 | 15 | Citations (PDF) |
| 7 | Addressing Comorbidities in People with Parkinson’s Disease: Considerations From An Expert Panel | 3.3 | 8 | Citations (PDF) |
| 8 | Economic Burden of Parkinson’s Disease: A Multinational, Real-World, Cost-of-Illness Study | 1.5 | 82 | Citations (PDF) |
| 9 | Diplopia in Movement Disorders: A Systematic Review of the Literature | 2.4 | 8 | Citations (PDF) |
| 10 | Parkinson's disease and vitamins: a focus on vitamin B12 | 3.4 | 20 | Citations (PDF) |
| 11 | The Impact of Fatigue on Sleep and Other Non-Motor Symptoms in Parkinson’s Disease | 2.4 | 22 | Citations (PDF) |
| 12 | Dietary Caffeine and Brain Dopaminergic Function in Parkinson Disease | 6.6 | 7 | Citations (PDF) |
| 13 | Non-Surgical Periodontal Therapy’s Influence on Alpha-Synuclein and Inflammatory Marker Levels: A Pilot Study | 2.5 | 2 | Citations (PDF) |
| 14 | Risk of Dementia in Parkinson's Disease: A Systematic Review and Meta‐Analysis | 4.6 | 38 | Citations (PDF) |
| 15 | Pain in Multiple System Atrophy: A Community‐Based Survey | 4.6 | 5 | Citations (PDF) |
| 16 | Exploring Analysis Approaches for Using the Dopamine Transporter Striatal Binding Ratio in Early‐ to Mid‐Stage Parkinson's Disease Modification Trials | 1.5 | 0 | Citations (PDF) |
| 17 | Vestibular Neurostimulation for Parkinson’s Disease: A Novel Device-Aided Non-Invasive Therapeutic Option | 2.4 | 1 | Citations (PDF) |
| 18 | What is known about the challenges people with Parkinson’s disease experience with their medicines and what solutions have been explored to overcome them? A scoping review | 0.6 | 0 | Citations (PDF) |
| 19 | Subthalamic Stimulation Improves Short-Term Satisfaction with Life and Treatment in Parkinson’s Disease | 2.4 | 3 | Citations (PDF) |
| 20 | External Factors Modulating Pain and Pain‐Related Functional Impairment in Cervical Dystonia | 1.5 | 4 | Citations (PDF) |
| 21 | The first cross-sectional comparative observational study of sexual dysfunction in Emirati and non-Emirati Parkinson’s disease patients (EmPark-SD) in the United Arab Emirates | 3.4 | 2 | Citations (PDF) |
| 22 | A scoping review of neurodegenerative manifestations in explainable digital phenotyping | 7.0 | 44 | Citations (PDF) |
| 23 | Revisiting Alpha-Synuclein Pathways to Inflammation | 4.4 | 21 | Citations (PDF) |
| 24 | Hiccups, Hypersalivation, Hallucinations in Parkinson’s Disease: New Insights, Mechanisms, Pathophysiology, and Management | 2.4 | 11 | Citations (PDF) |
| 25 | The noradrenergic subtype of Parkinson disease: from animal models to clinical practice | 28.6 | 74 | Citations (PDF) |
| 26 | The Pain in Dystonia Scale (PIDS)—Development and Validation in Cervical Dystonia | 4.6 | 16 | Citations (PDF) |
| 27 | Opicapone versus entacapone: Head‐to‐head retrospective data‐based comparison of healthcare resource utilization in people with Parkinson's disease new to catechol‐O‐methyltransferase (COMT) inhibitor treatment | 3.5 | 11 | Citations (PDF) |
| 28 | The Park Sleep subtype in Parkinson’s disease: from concept to clinic | 2.1 | 15 | Citations (PDF) |
| 29 | SARS-CoV-2 and Parkinson’s Disease: A Review of Where We Are Now | 3.4 | 13 | Citations (PDF) |
| 30 | Pain in Multiple System Atrophy a Systematic Review and Meta‐Analysis | 1.5 | 3 | Citations (PDF) |
| 31 | The neuropsychiatry of Parkinson's disease: advances and challenges | 17.9 | 419 | Citations (PDF) |
| 32 | Psychometric Properties of Clinical Indicators for Identification and Management of Advanced Parkinson’s Disease: Real-World Evidence From G7 Countries | 3.8 | 9 | Citations (PDF) |
| 33 | New approaches to treatments for sleep, pain and autonomic failure in Parkinson's disease - Pharmacological therapies | 4.3 | 13 | Citations (PDF) |
| 34 | Coronavirus Disease 2019 and Related Parkinsonism: The Clinical Evidence Thus Far | 1.5 | 23 | Citations (PDF) |
| 35 | Self-reported periodontitis and C-reactive protein in Parkinson’s disease: a cross-sectional study of two American cohorts | 7.0 | 20 | Citations (PDF) |
| 36 | Gender gap in deep brain stimulation for Parkinson’s disease | 7.0 | 59 | Citations (PDF) |
| 37 | Cost-effectiveness analysis of the Parkinson’s KinetiGraph and clinical assessment in the management of Parkinson's disease | 2.2 | 16 | Citations (PDF) |
| 38 | Characterization of Non‐Motor Fluctuations Using the Movement Disorder Society Non‐Motor Rating Scale | 1.5 | 15 | Citations (PDF) |
| 39 | First Two-Year Observational Exploratory Real Life Clinical Phenotyping, and Societal Impact Study of Parkinson’s Disease in Emiratis and Expatriate Population of United Arab Emirates 2019–2021: The EmPark Study | 2.4 | 10 | Citations (PDF) |
| 40 | Comparative Effectiveness of Device-Aided Therapies on Quality of Life and Off-Time in Advanced Parkinson’s Disease: A Systematic Review and Bayesian Network Meta-analysis | 6.3 | 35 | Citations (PDF) |
| 41 | Prevalence of Non‐Motor Symptoms and Non‐Motor Fluctuations in Parkinson's Disease Using the MDS‐NMS | 1.5 | 82 | Citations (PDF) |
| 42 | The Non‐Motor Symptoms Scale in Parkinson’s disease: Validation and use | 2.9 | 104 | Citations (PDF) |
| 43 | Non-motor complications in late stage Parkinson’s disease: recognition, management and unmet needs | 2.8 | 37 | Citations (PDF) |
| 44 | Nonmotor symptom burden grading as predictor of cognitive impairment in Parkinson’s disease | 2.4 | 9 | Citations (PDF) |
| 45 | Reply to Comment on: Successful Treatment of Levodopa/Carbidopa Intestinal Gel Associated “Biphasic‐Like” Dyskinesia with Pallidal Deep Brain Stimulation | 1.5 | 0 | Citations (PDF) |
| 46 | Parkinson's Disease and Post–COVID‐19 Syndrome: The Parkinson's Long‐COVID Spectrum | 4.6 | 68 | Citations (PDF) |
| 47 | REPRINTED WITH PERMISSION OF IASP – PAIN 162 (2021) 999–1006: Pain in the neurodegenerating brain: insights into pharmacotherapy for Alzheimer disease and Parkinson disease | 0.1 | 0 | Citations (PDF) |
| 48 | Non-motor predictors of 36-month quality of life after subthalamic stimulation in Parkinson disease | 7.0 | 45 | Citations (PDF) |
| 49 | Parkinson disease-associated cognitive impairment | 46.9 | 1,189 | Citations (PDF) |
| 50 | DUOGLOBE: One‐Year Outcomes in a Real‐World Study of Levodopa Carbidopa Intestinal Gel for Parkinson's Disease | 1.5 | 41 | Citations (PDF) |
| 51 | The Parkinson disease pain classification system: results from an international mechanism-based classification approachPain, 2021, 162, 1201-1210 | 4.2 | 99 | Citations (PDF) |
| 52 | Pain in the neurodegenerating brain: insights into pharmacotherapy for Alzheimer disease and Parkinson diseasePain, 2021, 162, 999-1006 | 4.2 | 34 | Citations (PDF) |
| 53 | The Movement Disorder Society Nonmotor Rating Scale: Initial Validation Study | 4.6 | 107 | Citations (PDF) |
| 54 | ‘Dopamine agonist Phobia’ in Parkinson’s disease: when does it matter? Implications for non-motor symptoms and personalized medicine | 2.8 | 19 | Citations (PDF) |
| 55 | Improving the Delivery of Levodopa in Parkinson’s Disease: A Review of Approved and Emerging Therapies | 6.3 | 50 | Citations (PDF) |
| 56 | Dyskinesia Matters: But Not as Much as It Used to | 4.6 | 4 | Citations (PDF) |
| 57 | Factor Analysis and Clustering of the Movement Disorder Society–Non‐Motor Rating Scale | 4.6 | 15 | Citations (PDF) |
| 58 | Genome‐Wide Association Study of Pain in Parkinson's Disease Implicates TRPM8 as a Risk Factor | 4.6 | 13 | Citations (PDF) |
| 59 | Impulse control and related behaviors in Parkinson’s disease with dementia | 3.5 | 19 | Citations (PDF) |
| 60 | Potential of animal models for advancing the understanding and treatment of pain in Parkinson’s disease | 7.0 | 101 | Citations (PDF) |
| 61 | Outcome of Parkinson's Disease Patients Affected by COVID‐19 | 4.6 | 218 | Citations (PDF) |
| 62 | Can therapeutic strategies prevent and manage dyskinesia in Parkinson’s disease? An update | 2.6 | 36 | Citations (PDF) |
| 63 | Acupuncture Effect and Mechanism for Treating Pain in Patients With Parkinson's Disease | 2.3 | 55 | Citations (PDF) |
| 64 | Sleep disturbances and gastrointestinal dysfunction are associated with thalamic atrophy in Parkinson’s disease | 2.1 | 11 | Citations (PDF) |
| 65 | Pilot Study of the International Parkinson and Movement Disorder Society‐sponsored Non‐motor Rating Scale (MDS‐NMS) | 1.5 | 49 | Citations (PDF) |
| 66 | EuroInf 2: Subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson's disease | 4.6 | 174 | Citations (PDF) |
| 67 | Exploring hyperhidrosis and related thermoregulatory symptoms as a possible clinical identifier for the dysautonomic subtype of Parkinson’s disease | 3.4 | 38 | Citations (PDF) |
| 68 | Pain in Parkinson's disease: new concepts in pathogenesis and treatment | 3.8 | 89 | Citations (PDF) |
| 69 | Update on treatments for nonmotor symptoms of Parkinson's disease—an evidence‐based medicine review | 4.6 | 915 | Citations (PDF) |
| 70 | Relationship of Nocturnal Sleep Dysfunction and Pain Subtypes in Parkinson's Disease | 1.5 | 27 | Citations (PDF) |
| 71 | Burden of non‐motor symptoms in Parkinson's disease patients predicts improvement in quality of life during treatment with levodopa‐carbidopa intestinal gel | 3.5 | 27 | Citations (PDF) |
| 72 | Serotonergic dysregulation is linked to sleep problems in Parkinson's disease | 3.3 | 90 | Citations (PDF) |
| 73 | Nonmotor symptoms evolution during 24 months of bilateral subthalamic stimulation in Parkinson's disease | 4.6 | 87 | Citations (PDF) |
| 74 | Pain in Parkinson's disease: facts and uncertainties | 3.5 | 102 | Citations (PDF) |
| 75 | Comprehensive grading of Parkinson’s disease using motor and non-motor assessments: addressing a key unmet need | 2.8 | 37 | Citations (PDF) |
| 76 | Constipation is not associated with dopamine transporter pathology in early drug‐naïve patients with Parkinson's disease | 3.5 | 25 | Citations (PDF) |
| 77 | The Parkinson's Disease Composite Scale: results of the first validation study | 3.5 | 25 | Citations (PDF) |
| 78 | A study investigating the experience of working for people with Parkinson’s and the factors that influence workplace success | 2.5 | 13 | Citations (PDF) |
| 79 | First comprehensive tool for screening pain in Parkinson's disease: the King's Parkinson's Disease Pain Questionnaire | 3.5 | 37 | Citations (PDF) |
| 80 | Motor and Nonmotor Complications of Levodopa: Phenomenology, Risk Factors, and Imaging Features | 4.6 | 115 | Citations (PDF) |
| 81 | Noninvasive Options for ‘Wearing-off’ in Parkinson’s Disease: A Clinical Consensus From a Panel of Uk Parkinson’s Disease Specialists | 2.7 | 26 | Citations (PDF) |
| 82 | Assessment and Management of Neuropsychiatric Symptoms in Parkinson’s Disease | 6.3 | 68 | Citations (PDF) |
| 83 | Amyloid-β and Parkinson’s disease | 3.4 | 133 | Citations (PDF) |
| 84 | Urinary dysfunction in early de novo patients with Parkinson's disease | 4.6 | 11 | Citations (PDF) |
| 85 | Distribution and impact on quality of life of the pain modalities assessed by the King’s Parkinson’s disease pain scale | 7.0 | 43 | Citations (PDF) |
| 86 | Letter to the editor: Automated night-time deep brain stimulation battery checks can induce symptoms: Identification and management of a new hardware complication | 1.5 | 0 | Citations (PDF) |
| 87 | The cost-effectiveness of levodopa/carbidopa intestinal gel compared to standard care in advanced Parkinson’s disease | 2.2 | 27 | Citations (PDF) |
| 88 | Self‐Assessment of Disability in Parkinson's Disease: The MDS‐UPDRS Part II Versus Clinician‐Based Ratings | 1.5 | 22 | Citations (PDF) |
| 89 | Non motor symptoms in progressive supranuclear palsy: prevalence and severity | 7.0 | 40 | Citations (PDF) |
| 90 | A Consensus Set of Outcomes for Parkinson’s Disease from the International Consortium for Health Outcomes Measurement | 3.3 | 62 | Citations (PDF) |
| 91 | Non-Motor Symptoms in Patients Suffering from Motor Neuron Diseases | 2.3 | 55 | Citations (PDF) |
| 92 | Night‐time sleep in Parkinson's disease – the potential use of Parkinson's KinetiGraph: a prospective comparative study | 3.5 | 51 | Citations (PDF) |
| 93 | Analysis of four scales for global severity evaluation in Parkinson’s disease | 7.0 | 33 | Citations (PDF) |
| 94 | Impulse control disorder related behaviours during long‐term rotigotine treatment: a post hoc analysis | 3.5 | 60 | Citations (PDF) |
| 95 | Rating Scales for Pain in Parkinson's Disease: Critique and Recommendations | 1.5 | 61 | Citations (PDF) |
| 96 | Parkinson's Impulse‐Control Scale for the Severity Rating of Impulse‐Control Behaviors in Parkinson's Disease: A Semistructured Clinical Assessment Tool | 1.5 | 29 | Citations (PDF) |
| 97 | Clinically relevant cut-off values for the Parkinson's Disease Sleep Scale-2 (PDSS-2): a validation study | 1.6 | 69 | Citations (PDF) |
| 98 | Accuracy of screening instruments for detection of neuropsychiatric syndromes in Parkinson's disease | 4.6 | 65 | Citations (PDF) |
| 99 | New clinical trials for nonmotor manifestations of Parkinson's disease | 4.6 | 86 | Citations (PDF) |
| 100 | The range and nature of non-motor symptoms in drug-naive Parkinson’s disease patients: a state-of-the-art systematic review | 7.0 | 85 | Citations (PDF) |
| 101 | A Pilot Prospective, Multicenter Observational Study of Dopamine Agonist Withdrawal Syndrome in Parkinson's Disease | 1.5 | 28 | Citations (PDF) |
| 102 | Infusion Therapies and Development of Impulse Control Disorders in Advanced Parkinson Disease | 1.1 | 71 | Citations (PDF) |
| 103 | Small fiber neuropathy in Parkinson's disease: A clinical, pathological and corneal confocal microscopy study | 2.6 | 140 | Citations (PDF) |
| 104 | Assessing the non‐motor symptoms of Parkinson's disease: MDS‐UPDRS and NMS Scale | 3.5 | 94 | Citations (PDF) |
| 105 | Management of impulse control disorders in Parkinson's disease: Controversies and future approaches | 4.6 | 98 | Citations (PDF) |
| 106 | Neuropsychiatric symptoms and caregiver's burden in Parkinson's disease | 2.6 | 202 | Citations (PDF) |
| 107 | Impulse control dysfunction and dopamine agonist withdrawal syndrome in Genetic Parkinson’s: A case report | 0.4 | 5 | Citations (PDF) |
| 108 | Parkinson's disease severity levels and MDS-Unified Parkinson's Disease Rating Scale | 2.6 | 339 | Citations (PDF) |
| 109 | Non-Motor Symptoms Profile and Burden in Drug Naïve Versus Long-Term Parkinson's Disease Patients | 3.3 | 44 | Citations (PDF) |
| 110 | A review of current treatment strategies for restless legs syndrome (Willis–Ekbom disease) | 1.3 | 27 | Citations (PDF) |
| 111 | Perceptions of symptoms and expectations of advanced therapy for Parkinson’s disease: preliminary report of a Patient-Reported Outcome tool for Advanced Parkinson’s disease (PRO-APD) | 2.9 | 47 | Citations (PDF) |
| 112 | Rotigotine transdermal system and evaluation of pain in patients with Parkinson’s disease: a post hocanalysis of the RECOVER study | 1.9 | 62 | Citations (PDF) |
| 113 | Vanishing White Matter Disease Presenting as Opsoclonus Myoclonus Syndrome in Childhood—A Case Report and Review of the Literature | 1.7 | 8 | Citations (PDF) |
| 114 | Parkinson's disease and vision | 0.4 | 26 | Citations (PDF) |
| 115 | Unveiling relevant non-motor Parkinson's disease severity symptoms using a machine learning approach | 5.7 | 62 | Citations (PDF) |
| 116 | Nonmotor fluctuations in Parkinson disease | 1.0 | 347 | Citations (PDF) |
| 117 | Trial of CBT for impulse control behaviors affecting Parkinson patients and their caregivers | 1.0 | 189 | Citations (PDF) |
| 118 | A Proposal for a Comprehensive Grading of Parkinson's Disease Severity Combining Motor and Non-Motor Assessments: Meeting an Unmet Need | 2.3 | 110 | Citations (PDF) |
| 119 | Career mentorship for young neurologists in Europe | 1.0 | 0 | Citations (PDF) |
| 120 | Gender-related differences in the burden of non-motor symptoms in Parkinson’s disease | 3.4 | 275 | Citations (PDF) |
| 121 | Rotigotine effects on early morning motor function and sleep in Parkinson's disease: A double‐blind, randomized, placebo‐controlled study (RECOVER) | 4.6 | 433 | Citations (PDF) |
| 122 | Parkinson's disease sleep scale—validation of the revised version PDSS‐2 | 4.6 | 398 | Citations (PDF) |
| 123 | Wirkung von Apomorphin auf nicht motorische Symptome bei Morbus Parkinson | 0.2 | 1 | Citations (PDF) |
| 124 | Chronic Subcutaneous Infusion Therapy with Apomorphine in Advanced Parkinson's Disease Compared to Conventional Therapy: A Real Life Study of Non Motor Effect | 3.3 | 121 | Citations (PDF) |
| 125 | Fatigue in Parkinson's disease is linked to striatal and limbic serotonergic dysfunctionBrain, 2010, 133, 3434-3443 | 8.4 | 326 | Citations (PDF) |
| 126 | Practice Parameter: Treatment of nonmotor symptoms of Parkinson disease [RETIRED] | 1.0 | 266 | Citations (PDF) |
| 127 | International study on the psychometric attributes of the Non-Motor Symptoms Scale in Parkinson disease | 1.0 | 245 | Citations (PDF) |
| 128 | REM sleep behavior disorder and the risk of developing Parkinson disease or dementia | 1.0 | 19 | Citations (PDF) |
| 129 | Clinical risk–benefit assessment of dopamine agonists | 3.5 | 26 | Citations (PDF) |
| 130 | Patterns of treatment for restless legs syndrome in primary care in the United Kingdom | 2.7 | 3 | Citations (PDF) |
| 131 | A review of clinical management of Restless Legs Syndrome | 6.3 | 7 | Citations (PDF) |
| 132 | Long-term clinical and positron emission tomography outcome of fetal striatal transplantation in Huntington's disease | 6.3 | 114 | Citations (PDF) |
| 133 | The metric properties of a novel non‐motor symptoms scale for Parkinson's disease: Results from an international pilot study | 4.6 | 1,032 | Citations (PDF) |
| 134 | Nature and variants of idiopathic restless legs syndrome: observations from 152 patients referred to secondary care in the UK | 3.4 | 43 | Citations (PDF) |
| 135 | International multicenter pilot study of the first comprehensive self‐completed nonmotor symptoms questionnaire for Parkinson's disease: The NMSQuest study | 4.6 | 1,029 | Citations (PDF) |
| 136 | Myasthenia gravis—a rare presentation with tongue atrophy and fasciculation | 1.8 | 18 | Citations (PDF) |
| 137 | A multicentre longitudinal observational study of changes in self reported health status in people with Parkinson's disease left untreated at diagnosis | 6.3 | 142 | Citations (PDF) |
| 138 | Genetic aspects of restless legs syndrome | 1.6 | 16 | Citations (PDF) |
| 139 | Measuring brain stem and cerebellar damage in parkinsonian syndromes using diffusion tensor MRI | 1.0 | 144 | Citations (PDF) |
| 140 | Clinical assessment of nocturnal disability in Parkinson’s disease | 1.0 | 37 | Citations (PDF) |
| 141 | Nocturnal symptom complex in PD and its management | 1.0 | 64 | Citations (PDF) |
| 142 | The Parkinson's disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson's disease | 6.3 | 621 | Citations (PDF) |
| 143 | A randomised placebo controlled exploratory study of vitamin B-12, lofepramine, and L-phenylalanine (the "Cari Loder regime") in the treatment of multiple sclerosis | 6.3 | 63 | Citations (PDF) |
| 144 | A comparison of18F-dopa PET and inversion recovery MRI in the diagnosis of Parkinson’s disease | 1.0 | 76 | Citations (PDF) |
| 145 | Autonomic dysfunction in movement disorders | 3.8 | 73 | Citations (PDF) |
| 146 | MRI changes in multiple sclerosis following treatment with lofepramine and l-phenylalanine | 1.5 | 30 | Citations (PDF) |
| 147 | Correlating rates of cerebral atrophy in Parkinson's disease with measures of cognitive decline | 3.4 | 74 | Citations (PDF) |
| 148 | A study of excessive daytime sleepiness and its clinical significance in three groups of Parkinson's disease patients taking pramipexole, cabergoline and levodopa mono and combination therapy | 3.4 | 106 | Citations (PDF) |
| 149 | Phenotypic and neuropathologic heterogeneity of anti-Hu antibody-related paraneoplastic syndrome presenting with progressive dysautonomia: report of two cases | 1.9 | 25 | Citations (PDF) |
| 150 | Erythropoietin deficiency and anaemia in multiple system atrophy | 4.6 | 39 | Citations (PDF) |
| 151 | Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease | 4.6 | 128 | Citations (PDF) |
| 152 | Progression of Dysarthria and Dysphagia in Postmortem-Confirmed Parkinsonian Disorders | 6.8 | 417 | Citations (PDF) |
| 153 | Primary anticholinergic-responsive Pisa syndrome | 4.6 | 37 | Citations (PDF) |
| 154 | Parkinson's disease misdiagnosed as multiple system atrophy by sphincter electromyography | 3.4 | 28 | Citations (PDF) |
| 155 | Cortical dysfunction in non-demented Parkinson's disease patients: A combined 31P-MRS and 18FDG-PET studyBrain, 2000, 123, 340-352 | 8.4 | 225 | Citations (PDF) |
| 156 | Evidence for cortical dysfunction in clinically non-demented patients with Parkinson's disease: a proton MR spectroscopy study | 6.3 | 61 | Citations (PDF) |
| 157 | Time course of symptomatic orthostatic hypotension and urinary incontinence in patients with postmortem confirmed parkinsonian syndromes: a clinicopathological study | 6.3 | 182 | Citations (PDF) |
| 158 | Erythropoietin depletion and anaemia in diabetes mellitus | 2.9 | 112 | Citations (PDF) |
| 159 | Clinical features differentiating patients with postmortem confirmed progressive supranuclear palsy and corticobasal degeneration | 3.4 | 92 | Citations (PDF) |
| 160 | Limb contractures in levodopa-responsive parkinsonism: a clinical and investigational study of seven new cases | 3.4 | 33 | Citations (PDF) |
| 161 | Progression of falls in postmortem-confirmed Parkinsonian disorders | 4.6 | 152 | Citations (PDF) |
| 162 | Repetitive belching, aerophagia, and torticollis in Huntington's disease: A case report | 4.6 | 30 | Citations (PDF) |
| 163 | Retrospective application of a set of clinical diagnostic criteria for the diagnosis of multiple system atrophy | 3.4 | 53 | Citations (PDF) |
| 164 | Accuracy of the Clinical Diagnoses of Lewy Body Disease, Parkinson Disease, and Dementia With Lewy Bodies | 6.8 | 339 | Citations (PDF) |
| 165 | How far are we in understanding the cause of Parkinson's disease? | 6.3 | 1 | Citations (PDF) |
| 166 | What Is the Accuracy of the Clinical Diagnosis of Multiple System Atrophy? | 6.8 | 234 | Citations (PDF) |
| 167 | Changes in putamen N-acetylaspartate and choline ratios in untreated and levodopa-treated Parkinson's disease: A proton magnetic resonance spectroscopy study | 1.0 | 80 | Citations (PDF) |
| 168 | Use of apomorphine in parkinsonian patients with neuropsychiatric complications to oral treatment | 2.6 | 60 | Citations (PDF) |
| 169 | Which clinical features differentiate progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) from related disorders? A clinicopathological study | 8.4 | 154 | Citations (PDF) |
| 170 | Postprandial hypotension and parkinsonian state in parkinson's disease | 4.6 | 58 | Citations (PDF) |
| 171 | Unilateral abdominal muscle herniation with pain: a distinctive variant of diabetic radiculopathy 1997, 14, 803-807 | | 29 | Citations (PDF) |
| 172 | Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) | 1.0 | 457 | Citations (PDF) |
| 173 | Proton magnetic resonance spectroscopy of the striatum in Parkinson's disease patients with motor response fluctuations | 2.6 | 17 | Citations (PDF) |
| 174 | No Association between Parkinson's Disease and Low-Activity Alleles of CatecholO-Methyltransferase | 2.1 | 84 | Citations (PDF) |
| 175 | Human immunodeficiency virus-related progressive multifocal leukoencephalopathy presenting with an akinetic rigid syndrome | 4.6 | 8 | Citations (PDF) |
| 176 | The moving ear syndrome: a focal dyskinesia. | 6.3 | 17 | Citations (PDF) |
| 177 | Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study. | 6.3 | 380 | Citations (PDF) |
| 178 | Central defects of autonomic function in secondary progressive multiple sclerosis: observations based on cardiovascular and growth hormone responses to clonidine | 3.5 | 3 | Citations (PDF) |
| 179 | Magnetic resonance spectroscopic study of parkinsonism related to boxing. | 6.3 | 5 | Citations (PDF) |
| 180 | Alcohol ingestion lowers supine blood pressure, causes splanchnic vasodilatation and worsens postural hypotension in primary autonomic failure | 3.4 | 33 | Citations (PDF) |
| 181 | Expression of β-Adrenoceptors on Circulating Mononuclear Cells in Hypertensives and Normotensives Before and After Reduction of Central Sympathetic Outflow by Clonidine | 1.7 | 9 | Citations (PDF) |
| 182 | Physiological assessment of aspects of autonomic function in patients with secondary progressive multiple sclerosis | 3.4 | 73 | Citations (PDF) |
| 183 | Effects of Oral Alcohol on Superior Mesenteric Artery Blood Flow in Normal Man, Horizontal and Tilted | 6.2 | 20 | Citations (PDF) |
| 184 | Cardiovascular and hormonal responses to liquid food challenge in idiopathic Parkinson's disease, multiple system atrophy, and pure autonomic failure | 1.0 | 38 | Citations (PDF) |
| 185 | Differential responses in superior mesenteric artery blood flow may explain the variant pressor responses to clonidine in two groups with sympathetic denervation | 6.2 | 12 | Citations (PDF) |
| 186 | Abnormality of superior mesenteric artery blood flow responses in human sympathetic failure. | 3.4 | 60 | Citations (PDF) |
| 187 | Growth hormone response to clonidine in central and peripheral primary autonomic failure | 62.1 | 50 | Citations (PDF) |
| 188 | Noninvasive quantification of superior mesenteric artery blood flow during sympathoneural activation in normal subjects | 1.9 | 44 | Citations (PDF) |
| 189 | Value of non-invasive continuous blood pressure monitoring in the detection of carotid sinus hypersensitivity | 1.9 | 17 | Citations (PDF) |
| 190 | A CASE OF SYSTEMIC LUPUS ERYTHEMATOSUS PRESENTING AS GUILLAIN-BARRÉ SYNDROME | 1.9 | 37 | Citations (PDF) |
| 191 | LIMITED JOINT MOBILITY AND CARPAL TUNNEL SYNDROME IN INSULIN-DEPENDENT DIABETES | 1.9 | 32 | Citations (PDF) |
| 192 | Lower Urinary Tract Symptoms Correlation With Motor and Cognitive Function in Patients With Parkinson Disease | 1.6 | 0 | Citations (PDF) |
| 193 | Improvement in Motor Consistency and Stability with Foslevodopa/Foscarbidopa in Advanced Parkinson’s Disease: Post Hoc Analysis of Two Phase 3 Clinical Trials | 3.8 | 0 | Citations (PDF) |
| 194 | A Holistic Wellness Prescription for Parkinson's Disease: Evidence‐Based Perspectives and Unmet Needs | 1.5 | 4 | Citations (PDF) |
| 195 | The challenges with the identification of Parkinson’s disease subtypes | 2.8 | 1 | Citations (PDF) |
| 196 | Clinical Efficacy, Cost-Effectiveness, and Caregiver Satisfaction in Clinical Practice Compared to Standard Care: 12-Month Longitudinal Analysis of the Application of Parkinson’s KinetiGraph | 0.8 | 0 | Citations (PDF) |
| 197 | What are the experiences and challenges people with Parkinson’s disease and their carers have with their Parkinson’s medications? A focus group study | 0.6 | 0 | Citations (PDF) |
| 198 | Foslevodopa–Foscarbidopa subcutaneous infusion in Parkinson’s disease: a cross-cultural/cross-racial international multicentre comparative tolerability study (CRIM-FOS study) | 3.4 | 0 | Citations (PDF) |
| 199 | Handgrip strength and relationship with non-motor symptoms in Parkinson's disease | 3.3 | 0 | Citations (PDF) |
